However, this classification system assumes that weight alone is a reliable indicator of health, disregarding important variables such as body composition, muscle mass, and bone density. These assumptions are increasingly being challenged, particularly when it comes to diverse ethnic groups.

The US will most likely remain a WHO member state but impose conditions, such increased contributions from other member states and oversight of mainland China.

New research exposes critical flaws in BMI measurements, as medical experts advocate for more accurate and inclusive methods to assess health and body composition.

including the World Health Organization and the US Centers for Disease Control and Prevention, define adult obesity as a BMI of 30 or greater and overweight as a BMI between 25 and 29.9. Recently ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass index, that could change clinical care.

More than half of Americans believe the U.S. benefits from its membership in the WHO. As of April 2024, 25% of U.S. adults say the country benefits a great deal from its membership, while about one-third say it benefits a fair amount. Conversely, 38% say the U.S. does not benefit much or at all from WHO membership.

The number does not capture a person's muscle mass; where on their body fat is stored; or how their race, ethnicity and gender affect health risks.

The way the world defines obesity has been in need of an overhaul, according to some experts, and it could be coming soon thanks to a new set of standards.

Trump withdraws US from WHO, obesity measurement overhaul, exercise benefits neurons, and more health updates in one place.

A cross-sectional study conducted at a leading tertiary care medical institute in Mumbai sheds light on the alarming prevalence of hypertension among young MBBS students and highlights actionable insights for intervention.

Analysis by researchers associated with institutions including Mumbai's Indian Institute of Population Sciences & Post Graduate Institute of Medical Education and Research, Chandigarh.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.